Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 3/20 | 0.67 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.67 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.67 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.67 |
| ▸ | SELP | P16109 | 1/20 | 0.64 |
| ▸ | DGKA | P23743 | 1/20 | 0.57 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.56 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.56 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.56 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1893444 | 1.00 | PRKCA (0.67) | PRKCAPRKCEPRKCQPRKCDSELP | |
| SCHEMBL457068 | 1.00 | PRKCA (0.67) | PRKCAPRKCEPRKCQPRKCDSELP | |
| SCHEMBL7076073 | 1.00 | PRKCA (0.67) | PRKCAPRKCEPRKCQPRKCDSELP | |
| SCHEMBL3403845 | 1.00 | PRKCA (0.67) | PRKCAPRKCEPRKCQPRKCDSELP | |
| SCHEMBL3408924 | 0.97 | SELP (0.69) | PRKCAPRKCEPRKCQPRKCDSELP | |
| SCHEMBL2228662 | 0.96 | SELP (0.68) | PRKCAPRKCEPRKCQPRKCDSELP | |
| SCHEMBL4195003 | 0.94 | PRKCA (0.60) | PRKCAPRKCEPRKCQPRKCDSELP | |
| SCHEMBL3408169 | 0.94 | SELP (0.65) | PRKCAPRKCEPRKCQPRKCDSELP | |
| SCHEMBL41701 | 0.94 | ALDH1A1 (0.63) | PRKCAPRKCEPRKCQPRKCDSELP | |
| SCHEMBL3409080 | 0.94 | ALDH1A1 (0.63) | PRKCAPRKCEPRKCQPRKCDSELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 490 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115316-A1 | LIPID NANOPARTICLES FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE, AND METHOD FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE USING SAME | NOF CORPORATION (JP) | 2026-04-30 | — | — | US | claimed |
| US-20250241948-A1 | Engineered Extracellular Vesicle Delivery Systems and Uses Thereof | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2025-07-31 | — | — | US | claimed |
| WO-2025129271-A1 | LIPID DELIVERY VEHICLE | THE UNIVERSITY OF QUEENSLAND (AU) | 2025-06-26 | — | — | WO | claimed |
| CN-119424366-A | Lipid nanoparticle targeting secondary lymphoid organ and preparation method and application thereof | 北京启辰生生物科技有限公司 | 2025-02-14 | — | — | CN | claimed |
| WO-2025029126-A1 | OXYGEN-CARRYING NANOLIPOSOME AND USE THEREOF | 최종훈 | 2025-02-06 | — | — | WO | claimed |
| EP-4501360-A1 | LIPID NANOPARTICLES FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE, AND METHOD FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE USING SAME | NOF Corporation (JP) | 2025-02-05 | — | — | EP | claimed |
| WO-2024019542-A1 | ULTRASONIC-RESPONSIVE PORPHYRIN-LIPOSOME AND USE THEREOF | (주)아이엠지티 | 2024-01-25 | — | — | WO | claimed |
| WO-2023190176-A1 | LIPID NANOPARTICLES FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE, AND METHOD FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE USING SAME | 日油株式会社 | 2023-10-05 | — | — | WO | claimed |
| WO-2023045036-A1 | MRNA DELIVERY SYSTEM AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 深圳市人民医院 | 2023-03-30 | — | — | WO | claimed |
| CN-113786391-B | mRNA delivery system and preparation method and application thereof | 深圳市人民医院 | 2022-07-26 | — | — | CN | claimed |
| US-20090285881-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-11-19 | — | — | US | claimed |
| WO-2009129385-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-10-22 | — | — | WO | claimed |
| WO-2009129387-A2 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-10-22 | — | — | WO | claimed |
| WO-2009129395-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-10-22 | — | — | WO | claimed |
| EP-2010150-A2 | STABLE EMULSION FORMULATIONS | Amgen Inc. (US) | 2009-01-07 | — | — | EP | claimed |
| US-20080199410-A1 | Pulmonary surfactant formulations and methods for promoting mucus clearance | DISCOVERY LABORATORIES, INC. | 2008-08-21 | — | — | US | claimed |
| US-20080181928-A1 | COATINGS FOR IMPLANTABLE MEDICAL DEVICES FOR LIPOSOME DELIVERY | MIV THERAPEUTICS, INC. (CA) | 2008-07-31 | — | — | US | claimed |
| WO-2008077248-A1 | COATINGS FOR IMPLANTABLE MEDICAL DEVICES FOR LIPOSOME DELIVERY | MIV THERAPEUTICS INC. (CA) | 2008-07-03 | — | — | WO | claimed |
| WO-2007124465-A2 | STABLE EMULSION FORMULATIONS | AMGEN INC. (US) | 2007-11-01 | — | — | WO | claimed |
| US-20070249520-A1 | STABLE EMULSION FORMULATIONS | AMGEN INC. (US) | 2007-10-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115316-A1 | LIPID NANOPARTICLES FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE, AND METHOD FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE USING SAME | SREBF1, SREBF2, FABP1 | PRKCA 1327/4885PRKCE 1888/4885PRKCQ 2988/4885 |
| US-20080181928-A1 | COATINGS FOR IMPLANTABLE MEDICAL DEVICES FOR LIPOSOME DELIVERY | LIPA, SGMS2, SGMS1 | PRKCA 2650/4885PRKCE 2425/4885PRKCQ 2540/4885 |
| US-20070249520-A1 | STABLE EMULSION FORMULATIONS | CALCR, CALCB, CALCRL | PRKCA 1939/4885PRKCE 978/4885PRKCQ 660/4885 |
| US-20090285881-A1 | CATIONIC LIPIDS AND USES THEREOF | LIPA, SGMS2, SGMS1 | PRKCA 1996/4885PRKCE 2840/4885PRKCQ 1810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.